(MedPage Today) — BARCELONA — Chimeric antigen receptor (CAR) T-cell therapy for rheumatologic disease is now expanding out of academe into the commercial space, with encouraging new data reported here from a U.S.-based industry program.
A…
Source link : https://www.medpagetoday.com/meetingcoverage/eular/116040
Author :
Publish date : 2025-06-12 17:57:00
Copyright for syndicated content belongs to the linked Source.
